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Abstract The striking clinical benefits of intermittent
parathyroid hormone in osteoporosis have begun a new
era of skeletal anabolic agents. Recombinant human
parathyroid hormone (rhPTH) (1–34) is the first US Food
and Drug Administration–approved anabolic therapy. Its
use has been limited by the need for subcutaneous injection.
Newer delivery systems include transdermal and oral
preparations. Newer anabolic therapies include monoclonal
antibody to sclerostin, a potent inhibitor of osteoblasto-
genesis; and use of bone morphogenetic proteins and
parathyroid hormone–related protein PTHrP, a calcium-
regulating hormone similar to PTH.
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Introduction
The Wnt signaling pathway demonstrates a complex
network of proteins well known for their roles in
embryogenesis but also involving normal physiologic
processes of bone formation in response to loading and
unloading. The interaction between Wnt proteins and cell
surface receptors can result in a variety of intracellular
responses [1]. Studies have revealed the existence of
extensive crosstalk between numerous ligands, receptors,
and coreceptors, as well as between downstream intracel-
lular messengers [1]. The Wnt pathway involves a large
network of proteins that can regulate the production of Wnt
signaling molecules and interaction with receptors and
target cells, and the physiologic response of target cells that
result in exposure of cells to the extracellular Wnt ligands.
The canonical Wnt pathway describes events when Wnt
proteins bind to cell surface receptors in the Frizzled family,
causing the receptors to activate disheveled family proteins
and ultimately result in the change in the amount of β-
catenin that reaches the nucleus [1]. Several proteins have
been described that inhibit Wnt signaling [2]. One such
protein is sclerostin, which binds low-density lipoprotein
receptor-related protein (LRP) and inhibits Wnt signaling.
Antibodies to dickkopf and secreted frizzled-related protein
produce similar outcomes in animal models to sclerostin
[2]. This article discusses several anabolic agents, including
sclerostin, bone morphogenetic protein (BMP), and para-
thyroid hormone (PTH), and new delivery systems for
PTH.
Sclerostin
Sclerostin, a glycoprotein secreted by osteocytes and to a
lesser extent other cell types (vascular, kidney), is a potent
inhibitor of osteoblastogenesis. Sclerostin is secreted from
osteocytes and travels through the canaliculi to the bone
surface where it binds to coreceptors LRP5 and LRP6 and
prevents colocalization with frizzled protein and Wnt
signaling, thereby reducing osteoblastogenesis and bone
formation [3]. Loss-of-function mutations in SOST are
associated with an autosomal-recessive disorder, sclero-
steosis, which causes progressive bone overgrowth [4]. A
deletion downstream of the SOST gene, which results in
reduced sclerostin expression, is associated with a milder
form of the disease called van Buchem disease [5].
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The development of a monoclonal antibody to sclerostin
that can be administered subcutaneously has allowed
scientists to evaluate the effect of sclerostin blockade on
bone metabolism and bone mass. Li et al. [7] treated
estrogen-deficient osteopenic rats with biweekly subcuta-
neous treatment with 25 mg/kg of a monoclonal antibody to
sclerostin for 5 weeks and restored trabecular bone mass to
baseline levels. Surface-based histomorphometry deter-
mined that the increase in bone mass resulted from an
increase in bone mass at all skeletal envelopes, including
cancellous, cortical bone sites, and supervertebral sites. The
increase in bone mass and change in microarchitecture were
associated with improved bone strength in both the
appendicular and axial skeleton.
Sclerostin (SOST) is thought to function as a paracrine
inhibitor of canonical Wnt signaling on the preosteoblast
surface by binding to the Wnt coreceptors LRP5 and LRP6
and blocking their colocalization with the frizzled receptor
[8]. The bone-forming effects of the SOST antibody in
many ways resemble those of high-dose intermittent PTH
in rodents. Several studies have reported that sclerostin
gene expression and protein levels are reduced in animals
treated with daily injections of human parathyroid hormone
(hPTH) (1–34) [9]. Preclinical studies with a sclerostin
inhibitor appear to be somewhat different from those with
hPTH (1–34). For example, all skeletal sites respond to
anabolic daily PTH treatment; the trabecular bone is most
responsive, followed by the endosteal surface and the
periosteal surface. In contrast, inhibition of sclerostin also
results in significant bone formation at the periosteal
surface. Also, studies find the increases in bone formation
induced by antisclerostin antibody, unlike PTH, are not
associated with increases in bone resorption in the aged
rodent skeleton.
Reduced mechanical stimulation leads to disuse osteo-
porosis, as seen in bedridden patients and in astronauts. Lin
et al. recently [10] reported that SOST knockout mice were
resistant to mechanical unloading bone loss. In contrast to
wild-type mice [9], Wnt/β-catenin signaling was not altered
by unloading in SOST knockout mice. The data suggest a
potential major role for sclerostin in mediating the bone
response to unloading and propose it may be a promising
target for preventing disuse osteoporosis [9].
At this time, the monoclonal antibody to sclerostin in is
early phase 2 clinical trials in postmenopausal women with
osteoporosis and in fracture healing studies, leaving only
phase 1 clinical safety data and short-term preclinical
studies. The long-term safety of sclerostin has not been
addressed. Additional clinical study data are needed to
determine the rapid gain in bone mass is associated with
bone of normal strength and architecture, if boney
overgrowth occurs at areas such as the carpal tunnel
resulting in carpal tunnel syndrome, or around the lumbar
spine neural foramen resulting in lumbar radiculopathy or
spinal stenosis. In summary, treatments based on inhibition
of sclerostin may be a powerful way to restore bone
strength of the osteoporotic skeleton in our patients and
potentially to provide more efficacious protection from hip
fracture than current therapies.
Bone Morphogenetic Proteins
BMPs are members of the transforming growth factor-β
superfamily. Bone morphogenic proteins are being used
successfully clinically for treating spinal fusion, delayed
fracture healing, and nonunion [10]. Multiple in vitro and in
vivo studies and clinical trials show a strong effect of BMP-2
and BMP-7 in terms of inducing bone [11–13]. Clinical
application is currently restricted in part due to cost. BMP-2
is used for open tibial fractures and spinal fusions, whereas
BMP-7 is used for nonunion with limited indication for spinal
fusion [14]. BMPs appear to be as good as iliac crest bone
graft or even more effective with moderate side effects [10].
There is a need for anabolic agents such as BMP for
patients with delayed fracture healing or nonunion. A
literature review on tibial fracture healing reveals that
16.7% of patients showed delayed fracture healing or a
nonunion, and 11.8% developed malunion with up to 23%
requiring operative reintervention [15]. Successful bone
healing depends on two factors: 1) mechanical signaling
[16], which can be enhanced by biophysical stimulation
(eg, ultrasound, shockwaves, and electromagnetic fields), or
2) biological substances (eg, bone grafts, hormones, and
growth factors such as BMP) [17].
BMPs appear to be most beneficial for atrophic
nonunions, but may also be used for treating hypertrophic
nonunions. Treatment of bone defects in nonunion often
requires the use of additional grafting material, which may
be autogenous bone or potentially, in the future, the use of
stem cells. BMP-7 is often used in combination with
synthetic carriers based on tricalcium phosphate. BMP-2 is
approved for anterior lumbar interbody fusion, but also has
shown beneficial results in transforaminal lumbar applica-
tion in multiple clinical studies [17, 18]. In posterolateral
lumbar fusion, the use of BMP-2 was compared with iliac
crest bone graft and showed a significantly higher fusion
rate compared with control subjects [19].
Side effects of BMPs are moderate [19–21]. For posterior
fusion, heterotopic bone formation was found in the spinal
canal close to the cage, raising concerns about safety aspects
and that BMP should not be applied too close to the spinal
canal. Concerns also have been raised with transforaminal
lumbar interbody fusion in which initial vertebral resorption
24 Curr Osteoporos Rep (2010) 8:23–27or osteolysis was found, which resolved after 3 months.
Although BMP-2 has been felt to be safe and effective for
anterior cervical spine fusion, dysphagia has been noted,
possibly related to transient postoperative soft tissue swell-
ing, which usually disappears within a few days.
Preclinical and clinical safety assessments revealed little
evidence of toxic effects and few reports of adverse effects
such as ectopic bone formation, bone resorption, swelling,
and hematoma. A low level of immunologic reaction has
been seen with antibody responses detected in less than 1%
of patients.
Use of BMPs, however, is limited by their expensive
cost. Current use of BMPs requires an open approach; they
are currently applied in combination with collagen. Possible
new application strategies may include the local and
controlled injection of BMPs in combination with a
synthetic carrier, such as a calcium phosphate paste.
New Delivery Systems in Development for PTH
Treatments
Nearly 7 years ago, the US Food and Drug Administration
approved the first anabolic agent, recombinant human
parathyroid hormone (rhPTH) (1–34), the 34 amino acid
fragment of PTH, to be given on a daily basis by sub-
cutaneous injection for up to 2 years for treating postmen-
opausal osteoporosis [22]. PTH is anabolic because it
increases bone formation and bone mass, but it also
stimulates bone remodeling as part of its action. PTH
increases bone formation through several actions, including
increasing commitment of mesenchymal stem cells to the
osteoblast lineage, increasing osteoblast maturation and
possibly life span, and reducing the osteocyte production of
sclerostin to further stimulate bone formation. PTH stimu-
lation of osteoblastogenesis also increases receptor activator
of nuclear factor-κB ligand production, which then stim-
ulates osteoclast maturation and activity, increasing bone
remodeling overall; however, the overall effect is a positive
formation balance. Although rhPTH (1–34) is effective in
improving bone strength and incident fracture risk reduc-
tion, since it must be administered by daily subcutaneous
injection for up to 2 years, a number of osteoporotic
patients who might benefit from rhPTH (1–34) treatment do
not choose to be treated [23].
Because PTH (1–34) is a peptide hormone, many
potential challenges must be overcome to administer it
orally. In an attempt to develop a simplier mode of delivery
for PTH (1–34), a PTH (1–34) that is delivered by a
transdermal microneedle delivery system patch has been
developed and now tested in phase 1 and phase 2 clinical
trials. The PTH transdermal patch is composed of a small
adhesive patch that is coated with hPTH (1–34) on a
titanium microneedle array with 1,300 microneedles per
hPTH (1–34) patch [24, 25••, 26, 27]. A recent phase 2
clinical trial was completed that evaluated the effectiveness
of the transdermal hPTH (1–34) compared with rhPTH (1–
34) subcutaneous injections and a placebo patch on bone
mineral density (BMD) in postmenopausal women with
osteoporosis after 6 months of treatment. A total of 165
patients were enrolled in the study and randomized to an
hPTH (1–34) patch of 20 μg, 30 μg, 40 μg, or placebo, or
rhPTH (1–34) injections for 6 months. After 6 months of
therapy, subjects treated with all doses of the hPTH (1–34)
patch and the rhPTH (1–34) given subcutaneously had
significant gains in lumbar spine BMD (range, ∼3–5%
gain) compared with the placebo patch (−0.02%). In
addition, the average gain in total hip BMD in the hPTH
(1–34) 40-μg dose group was significantly greater than the
placebo group (∼1.5% compared with -0.5%), with no
significant change with the 20-µg or 30-µg dose. Changes
in the biochemical markers of bone turnover were some-
what different between the two deliver systems for PTH.
The rhPTH group had a gain in the bone formation marker,
P1NP, of nearly 300% and a rise in the bone resorption
marker, CTX-1, of nearly 100% over the baseline values.
The transdermal patch hPTH (1–34) 40-μg/d group had
gains in bone formation by P1NP of only 100%, and CTX-
1 of only about 40% [24].
The explanation for the greater change in BMD of the
lumbar spine and hip by the higher doses of the hPTH (1–34)
group may be that less bone remodeling was stimulated;
however; this is a hypothesis that will require additional
studies. One other interesting observation was that the mean
plasma concentrations of PTH (1–34) with transdermal
delivery peaked after about 5–10 min, whereas the peak was
nearly 30 min after the subcutaneous injection, and the serum
half-life after the transdermal administration was shorter
(∼60 min), whereas it was about 90 min with subcutaneous
administration [24]. The different pharmacokinetics between
these two delivery systems may explain the changes we
observe in bone turnover. However, phase 3 studies of longer
duration and more study subjects are needed to elucidate
these phase 2 study results.
Oral Delivery of PTH
A new formulation of PTH (1–34) is being developed as an
oral formulation as a way to make this treatment a more
convenient option for osteoporotic patients. The oral
formulation includes the PTH (1–34) protein and an
absorption enhancer, 5-CNAC [28]. A phase 1 study
enrolled 34 postmenopausal women and 16 subjects. The
subjects were randomized to receive placebo, rhPTH (1–
34), or 1, 2.5, 5, or 10 mg of oral PTH (1–34) formulated
Curr Osteoporos Rep (2010) 8:23–27 25with 200 mg of 5-CNAC, 16 patients were randomized to
receive up to six regimens of rhPTH (1–34) or 2.5 or 5 mg
of oral hPTH (1–34) with 100 or 200 mg of 5-CNAC, and
treatments were administered for at least 6 days [28]. They
reported all doses of the oral PTH were well absorbed and
serum concentrations increased in a dose-dependent man-
ner. The dose of PTH (1–34) of 2.5 or 5 mg combined with
the oral enhancer CNAC at 200 mg had an area under the
curve that was very similar to rhPTH (1–34) given by
subcutaneous injection. The side effects of rhPTH (1–34)
given by subcutaneous injections can be hypercalcemia;
however; in this phase 1 study, ionized calcium remained
within normal limits for all evaluated doses. Adverse events
reported that resulted in study subjects withdrawing from
the study were symptomatic hypotension (n=3 from the
PTH [1-34] at 2.5 or 5 mg with 200-mg CNAC; n=1
rhPTH [1-34]; n=1 placebo), three withdrew from pro-
longed vomiting (5-mg PTH [1–34] and 200-mg CNAC),
and symptomatic but unconfirmed hypercalcemia (n=1
from the PTH [1–34] at 2.5 mg with 100-mg CNAC) [28].
This novel oral delivery system for hPTH (1–34)
combined with an absorption enhancer CNAC appears to
show promise for treating osteoporosis. Additional studies
and refinement of the dosing regimen appear warranted to
enhance the use of this novel technology.
Parathyroid Hormone–Related Protein
Parathyroid hormone–related protein (PTHrP) is a hormone
that is closely related to another hormone discovered in the
1920s named parathyroid hormone (PTH). Similar to PTH,
PTHrP is also a hormone that regulates calcium metabolism.
PTH has been shown to be effective in treating osteoporosis
in animals and humans [29]. PTHrP has been shown to be
effective in treating osteoporosis in laboratory animals, and
there are strong scientific reasons to think that it may be
effective in humans also [30]. A study of PTHrP (1–36) was
performed to determine if it could increase bone mass in
postmenopausal women with osteoporosis when adminis-
tered daily by subcutaneous injection for 3 months [31].
The double-blind, placebo-controlled, randomized clini-
cal study enrolled 16 postmenopausal women with osteo-
porosis between 50 and 75 years of age [31]. All had been
on hormone replacement therapy for an average of 8 years
and still had osteoporosis. Women who had been taking
any other type of osteoporosis medication were excluded
from the study. Half of the participants received a self-
administered injection of PTHrP and the other half received
a placebo. The patients were followed up for 3 months and
the participants tolerated the treatment without developing
hypercalcemia, hypotension, nausea, flushing, or other
adverse effects. The lumbar spine BMD increased by
4.7% during the 3-month treatment period, a larger increase
in bone gain that is usually observed with the available
antiresorptive osteoporosis medications. Even though the
study was designed as a pilot, the results were surprisingly
more favorable than expected, and larger studies of longer
duration are needed to elucidate the full potential of this
bone-building agent and if the increase in bone mass can
reduce incident fracture risk.
Conclusions
We now have a diverse menu of osteoporosis therapies
including both antiresorptive and one anabolic therapy
(teriparatide). Current research suggests that in the future
we may have multiple different anabolic therapies such as
sclerostin, PTHrP, and other potential molecules, and
alternate delivery systems for administration. The therapies
may have orthopedic benefits in terms of fracture healing
and fusions. The future of anabolic therapies looks bright.
Disclosure No potential conflicts of interest relevant to this article
were reported.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
Papers of particular interest, published recently, have been
highlighted as follows:
•• Of major importance
1. van Amerongen R, Nusse R. Towards an integrated view of Wnt
signaling in development. Development 2009;136:3205–14.
2. Hoeppner LH, Secreto FJ, Westendorf JJ. Wnt signaling as a
therapeutic target for bone diseases. Expert Opin Ther Targets
2009;13:455–96.
3. Kneissel M. The promise of sclerostin inhibition for the treatment
of osteoporosis. IBMS BoneKEy 2009;6:259–64.
4. Balemans W, Ebeling M, Patel N, et al. Increased bone density in
sclerostin is due to the deficiency of a novel secreted protein
(SOST). Hum Mol Genet 2001;10:537–43.
5. Wengenroth M, Vasvari G, Federspil PA, et al. Case 150: Van
Buchem disease (hyperostosis corticalis generalisata). Radiology
209;253:272–76.
6. Li X, Ominsky MS, Nim QT, et al. Targeted deletion of sclerostin
gene in mice results in increased bone formation and strength. J
Bone Miner Res 2008;23:860–69.
7. Li X, Ominsky MS, Warmingtom KS, et al. Sclerostin antibody
treatment increases bone formation, bone mass and bone strength
in a rat model of postmenopausal osteoporosis. J Bone Miner Res
2009;24:574–88.
26 Curr Osteoporos Rep (2010) 8:23–278. Baron R, Rowadi G. Targeting the Wnt/beta-catenin pathway to
regulate bone formation in the adult skeleton. Endocrinology
2007;148:2635–43.
9. Bellido T. Downregulation of SOST (sclerostin) by PTH: a novel
mechanism of hormonal control of bone formation mediated by
osteocytes. J Musculoskelet Neuronal Interact 2006;6:358–9.
10. Lin C, Jiang X, Dai Z, et al. Sclerostin mediates bone response to
mechanical unloading through antagonizing Wnt/beta-catenin
signaling. J Bone Miner Res 2009;24:1651–61.
11. Schmidmaier G, Wildemann B. Perspectives: the role of BMPs in
current orthopedic practice. IBMS BoneKEy 2009;6:244–53.
12. Govender S, Csimma C, Genant HK, et al. BMP-2 Evaluation in
Surgery for Tibial Trauma (BESTT) Study Group. Recombinant
human bone morphogenetic protein-2 for treatment of open tibial
fractures:aprospective,controlled,randomizedstudyoffourhundred
and fifty patients. J Bone Joint Surg Am 2002;84A:2123–34.
13. Friedlander GE, Perry CR, Cole JD, et al. Osteogenic protein-1
(BMP-7) in treatment of tibial nonunions. J Bone Joint Surg Am
2001;83A(Suppl 1, Pt 2):S151–58.
14. Burkus JK, Gornet MF, Dickman CA, Zdeblick TA. Anterior
lumbar interbody fusion using rhBMP-2 with tapered interbody
cages. J Spinal Disord Tech 2002;15:337–49.
15. White AP, Vaccaro AR, Hall JA, et al. Clinical applications of
BMP-7/OP-1 in fractures, nonunions and spinal fusion. Int Orthop
2007;31:735–41.
16. Coles CP, Gross M. Closed tibial shaft fractures: management and
treatment complications. A review of the prospective literature.
Can J Surg 2000;43:256–62.
17. Chao EY, Inoue N. Biophysical stimulation of bone fracture
repair, regeneration and remodeling. Eur Cell Mater 2003;6:72–
84; discussion 84–85.
18. Singh K, Smucker JD, Gill S, Boden SD. Use of recombinant
human bone morphogenetic protein-2 as an adjunct in posterolat-
eral lumbar spine fusion: a prospective CT-scan analysis at one
and two years. J Spinal Disord Tech 2006;19:416–23.
19. Glassman SD, Dimar JR, Carreon LY, et al. Initial fusion rates
with recombinant human bone morphogenetic protein-2/compres-
sion resistant matrix and a hydroxyapatite and tricalcium
phosphate/collagen carrier in posterolateral spinal fusion. Spine
2005;30:1694–98.
20. Villavicencio AT, Burneikiene S, Nelson EL, et al. Safety of
transforaminal lumbar interbody fusion and intervertebral recom-
binant human bone morphogenetic protein-2. J Neurosurg Spine
2005;3:436–43.
21. Vaccaro AR, Lawrence JP, Patel T, et al. The safety and efficacy
of OP-1 (rhBMP-7) as a replacement for iliac crest autograft in
posterolateral lumbar arthrodesis: a long-term (>4 years) pivotal
study. Spine 2008;33:2850–62.
22. Poynton AR, Lane JM. Safety profile for the clinical use of bone
morphogenetic proteins in the spine. Spine 2002;27(16 Suppl 1):
S40–8.
23. Cosman F. Parathyroid hormone treatment of osteoporosis. Curr
Opin Endocrinol Diabetes Obes 2008;15:495–501.
24. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid
hormone (1–34) on fractures and bone mineral density in
postmenopausal women with osteoporosis. N Engl J Med
2001;344:1434–41.
25. •• Cosman F, Lane NE, Bolognese MA, et al. Effect of
transdermal teriparatide administration on bone mineral density
in postmenopausal women. J Clin Endocrin Metab 2009 Oct 26
[Epub ahead of print] This study demonstrates that the transder-
mal delivery of hPTH (1–34) was similar to the subcutaneous
injection of hPTH (1–34) in terms of increase in BMD with no
significant toxicity.
26. Cormier M, Johnson B, Ameri M, et al. Transdermal delivery of
desmopressin using coated microneedle array patch system. J
Control Release 2004;97:503–511.
27. Gopalakrishnan V, Hwang S, Loughrey H. Administration of
ThPTH to humans using Macroflux transdermal technology
results in the rapid delivery of biologically active PTH. J Bone
Miner Res 2004;19(Suppl 1):S460.
28. John MR, Haemmerle S, Launonen A, et al. A novel oral
parathyroid hormone formulation, PTH134, demonstrated a
potential therapeutically relevant pharmacokinetic and safety
profile compared with teriparatide s.c. in healthy postmenopausal
women after a single dose. Arthritis Rheum 2009;60(Suppl 1):
S333.
29. Stewart AF, Cain RL, Burr DB, et al. Six-month daily administra-
tion of parathyroid hormone and parathyroid hormone-related
protein peptides to adult ovariectomized rats markedly enhances
bone mass and biomechanical properties: a comparison of human
parathyroid hormone 1–34, parathyroid hormone-related protein 1–
36, and SDZ-parathyroid hormone 893. J Bone Miner Res
2000;15:1517–25.
30. Horwitz MJ, Tedesco MB, Garcia-Ocaña A, et al. Parathyroid
hormone-related protein for the treatment of postmenopausal
osteoporosis: defining the maximal tolerable dose. J Clin
Endocrinol Metab 2010 Jan 8 [Epub ahead of print].
31. Horwitz MJ, Tedesco MB, Gundberg C, et al. Short-term, high-
dose parathyroid hormone-related protein as a skeletal anabolic
agent for the treatment of postmenopausal osteoporosis. J Clin
Endocrinol Metab 2003;88:569–75.
Curr Osteoporos Rep (2010) 8:23–27 27